Bioconvergence & future human health, with Shai Melcer
Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.
Newsletters and Deep Dive digital magazine
Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.
Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.
A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.
Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.
Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.
Editor's Picks
Newsletters and Deep Dive
digital magazine